Synopsis
Synopsis
0
VMF
0
Australia
DRUG PRODUCT COMPOSITIONS0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 2(1h)-isoquinolinecarboxylic Acid, 3,4-dihydro-1-phenyl-,1- Azabicyclo(2.2.2)oct-3-yl Ester, (r-(r*,s*))-
2. 905, Ym
3. Quinuclidin-3'-yl-1-phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylate Monosuccinate
4. Solifenacin
5. Succinate, Solifenacin
6. Vesicare
7. Ym 905
8. Ym905
1. 242478-38-2
2. Vesicare
3. Solifenacin (succinate)
4. Solifenacin Succinate [usan]
5. Ym-905
6. Ym 905
7. Ym905
8. 1-azabicyclo[2.2.2]octan-8-yl (1s)-1-phenyl-3,4-dihydro-1h-isoquinoline-2-carboxylate Butanedioic Acid
9. Ym67905
10. Kka5dld701
11. Ym-67905
12. [(3r)-1-azabicyclo[2.2.2]octan-3-yl] (1s)-1-phenyl-3,4-dihydro-1h-isoquinoline-2-carboxylate;butanedioic Acid
13. Vesikur
14. (s)-(r)-quinuclidin-3-yl 1-phenyl-3,4-dihydroisoquinoline-2(1h)-carboxylate Succinate
15. Chembl1200803
16. Solifenacin Succinate Salt
17. Unii-kka5dld701
18. Vesicare Od
19. Vesicare (tn)
20. Isoprenalinoe Sulfate
21. Vesicare Ls
22. Solifenacin Succinate- Bio-x
23. Mls006010416
24. Schembl109333
25. Chebi:32151
26. Dtxsid30947075
27. Hms3887a13
28. Solifenacin Succinate [mi]
29. Solifenacin Succinate [jan]
30. Ex-a4170
31. Hy-a0002
32. Mfcd00954234
33. S3048
34. Solifenacin Succinate [vandf]
35. Solifenacin Succinate [mart.]
36. Akos015994745
37. Solifenacin Succinate [usp-rs]
38. Solifenacin Succinate [who-dd]
39. Am84825
40. Ccg-269551
41. Cs-0371
42. Ks-1286
43. Solifenacin Succinate (jan/usan/inn)
44. Solifenacin Succinate, >=98% (hplc)
45. [(3r)-1-azabicyclo[2.2.2]octan-3-yl] (1s)-1-phenyl-3,4-dihydro-1h-isoquinoline-2-carboxylate; Butanedioic Acid
46. 2(1h)-isoquinolinecarboxylic Acid, 3,4-dihydro-1-phenyl-, (3r)-1-azabicyclo(2.2.2)oct-3-yl Ester, (1s)-, Butanedioate (1:1)
47. As-35288
48. Bs164410
49. Butanedioic Acid, Cmpd. With (1s)-(3r)-1-azabicyclo(2.2.2)oct-3-yl 3,4-dihydro-1-phenyl-2(1h)-isoquinolinecarboxylate (1:1)
50. Butanedioic Acid, Compd With (1s)-(3r)-1-azabicyclo(2.2.2)oct-3-yl 3,4-dihydro-1-phenyl-2(1h)-isoquinolinecarboxylate (1:1)
51. Smr004701445
52. Ym-53705
53. Solifenacin Succinate [orange Book]
54. Solifenacin Succinate [ep Monograph]
55. S0944
56. Sw219141-1
57. D01269
58. A819262
59. A881133
60. Q374826
61. Solifenacin Succinate, Europepharmacopoeia (ep) Reference Standard
62. Solifenacin Succinate, United States Pharmacopeia (usp) Reference Standard
63. (r)-quinuclidin-3-yl (s)-1-phenyl-3,4-dihydroisoquinoline-2(1h)-carboxylate
64. (s)-(r)-quinuclidin-3-yl1-phenyl-3,4-dihydroisoquinoline-2(1h)-carboxylatesuccinate
65. Quinuclidin-3'-yl-1-phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylatemonosuccinate
66. Solifenacin For System Suitability, Europepharmacopoeia (ep) Reference Standard
67. (1s)-(3r)-1-azabicyclo[2.2.2]oct-3-yl-3,4-dihydro-1-phenyl-2(1h)-isoquinolinecarboxylate Succinate
68. 1-azabicyclo[2.2.2]octan-8-yl (1s)-1-phenyl-3,4-dihydro-1h-isoquinoline-2-carboxylate Butanedioic Acid (solifenacin?succinate)
69. Butanedioic Acid--1-azabicyclo[2.2.2]octan-3-yl 1-phenyl-3,4-dihydroisoquinoline-2(1h)-carboxylate (1/1)
70. Butanedioic Acid; (1s)-1-phenyl-3,4-dihydro-1h-isoquinoline-2-carboxylic Acid [(3r)-1-azabicyclo[2.2.2]octan-3-yl] Ester
| Molecular Weight | 480.6 g/mol |
|---|---|
| Molecular Formula | C27H32N2O6 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 7 |
| Rotatable Bond Count | 6 |
| Exact Mass | 480.22603674 g/mol |
| Monoisotopic Mass | 480.22603674 g/mol |
| Topological Polar Surface Area | 107 Ų |
| Heavy Atom Count | 35 |
| Formal Charge | 0 |
| Complexity | 617 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 2 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
| 1 of 4 | |
|---|---|
| Drug Name | Solifenacin succinate |
| Drug Label | VESIcare (solifenacin succinate) is a muscarinic receptor antagonist. Chemically, solifenacin succinate is butanedioic acid, compounded with (1S)-(3R)-1-azabicyclo[2.2.2]oct-3-yl 3,4-dihydro-1-phenyl-2(1H)-iso-quinolinecarboxylate (1:1) having an e... |
| Active Ingredient | Solifenacin succinate |
| Dosage Form | Tablet |
| Route | Oral |
| Strength | 5mg; 10mg |
| Market Status | Prescription |
| Company | Teva Pharms Usa |
| 2 of 4 | |
|---|---|
| Drug Name | Vesicare |
| PubMed Health | Solifenacin (By mouth) |
| Drug Classes | Urinary Antispasmodic |
| Drug Label | VESIcare (solifenacin succinate) is a muscarinic receptor antagonist. Chemically, solifenacin succinate is butanedioic acid, compounded with (1S)-(3R)-1-azabicyclo[2.2.2]oct-3-yl 3,4-dihydro-1-phenyl-2(1H)-iso-quinolinecarboxylate (1:1) having an e... |
| Active Ingredient | Solifenacin succinate |
| Dosage Form | Tablet |
| Route | Oral |
| Strength | 5mg; 10mg |
| Market Status | Prescription |
| Company | Astellas |
| 3 of 4 | |
|---|---|
| Drug Name | Solifenacin succinate |
| Drug Label | VESIcare (solifenacin succinate) is a muscarinic receptor antagonist. Chemically, solifenacin succinate is butanedioic acid, compounded with (1S)-(3R)-1-azabicyclo[2.2.2]oct-3-yl 3,4-dihydro-1-phenyl-2(1H)-iso-quinolinecarboxylate (1:1) having an e... |
| Active Ingredient | Solifenacin succinate |
| Dosage Form | Tablet |
| Route | Oral |
| Strength | 5mg; 10mg |
| Market Status | Prescription |
| Company | Teva Pharms Usa |
| 4 of 4 | |
|---|---|
| Drug Name | Vesicare |
| PubMed Health | Solifenacin (By mouth) |
| Drug Classes | Urinary Antispasmodic |
| Drug Label | VESIcare (solifenacin succinate) is a muscarinic receptor antagonist. Chemically, solifenacin succinate is butanedioic acid, compounded with (1S)-(3R)-1-azabicyclo[2.2.2]oct-3-yl 3,4-dihydro-1-phenyl-2(1H)-iso-quinolinecarboxylate (1:1) having an e... |
| Active Ingredient | Solifenacin succinate |
| Dosage Form | Tablet |
| Route | Oral |
| Strength | 5mg; 10mg |
| Market Status | Prescription |
| Company | Astellas |
Treatment of neurogenic detrusor overactivity
Urological Agents
Drugs used in the treatment of urological conditions and diseases such as URINARY INCONTINENCE and URINARY TRACT INFECTIONS. (See all compounds classified as Urological Agents.)
Muscarinic Antagonists
Drugs that bind to but do not activate MUSCARINIC RECEPTORS, thereby blocking the actions of endogenous ACETYLCHOLINE or exogenous agonists. Muscarinic antagonists have widespread effects including actions on the iris and ciliary muscle of the eye, the heart and blood vessels, secretions of the respiratory tract, GI system, and salivary glands, GI motility, urinary bladder tone, and the central nervous system. (See all compounds classified as Muscarinic Antagonists.)
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]CEP/COS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] EU WC
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]INTERMEDIATE SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Canada
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DRUG PRODUCT COMPOSITIONS
DOSAGE - TABLET;ORAL - 10MG
USFDA APPLICATION NUMBER - 21518
DOSAGE - TABLET;ORAL - 5MG
USFDA APPLICATION NUMBER - 21518
Digital Content
NEWS #PharmaBuzz
Global Sales Information
US Medicaid Prescriptions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ANALYTICAL
ABOUT THIS PAGE
88
PharmaCompass offers a list of Solifenacin Succinate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Solifenacin Succinate manufacturer or Solifenacin Succinate supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Solifenacin Succinate manufacturer or Solifenacin Succinate supplier.
PharmaCompass also assists you with knowing the Solifenacin Succinate API Price utilized in the formulation of products. Solifenacin Succinate API Price is not always fixed or binding as the Solifenacin Succinate Price is obtained through a variety of data sources. The Solifenacin Succinate Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Solifenacin Succinate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Solifenacin Succinate, including repackagers and relabelers. The FDA regulates Solifenacin Succinate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Solifenacin Succinate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Solifenacin Succinate manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Solifenacin Succinate supplier is an individual or a company that provides Solifenacin Succinate active pharmaceutical ingredient (API) or Solifenacin Succinate finished formulations upon request. The Solifenacin Succinate suppliers may include Solifenacin Succinate API manufacturers, exporters, distributors and traders.
click here to find a list of Solifenacin Succinate suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Solifenacin Succinate DMF (Drug Master File) is a document detailing the whole manufacturing process of Solifenacin Succinate active pharmaceutical ingredient (API) in detail. Different forms of Solifenacin Succinate DMFs exist exist since differing nations have different regulations, such as Solifenacin Succinate USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Solifenacin Succinate DMF submitted to regulatory agencies in the US is known as a USDMF. Solifenacin Succinate USDMF includes data on Solifenacin Succinate's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Solifenacin Succinate USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Solifenacin Succinate suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Solifenacin Succinate Drug Master File in Japan (Solifenacin Succinate JDMF) empowers Solifenacin Succinate API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Solifenacin Succinate JDMF during the approval evaluation for pharmaceutical products. At the time of Solifenacin Succinate JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Solifenacin Succinate suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Solifenacin Succinate Drug Master File in Korea (Solifenacin Succinate KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Solifenacin Succinate. The MFDS reviews the Solifenacin Succinate KDMF as part of the drug registration process and uses the information provided in the Solifenacin Succinate KDMF to evaluate the safety and efficacy of the drug.
After submitting a Solifenacin Succinate KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Solifenacin Succinate API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Solifenacin Succinate suppliers with KDMF on PharmaCompass.
A Solifenacin Succinate CEP of the European Pharmacopoeia monograph is often referred to as a Solifenacin Succinate Certificate of Suitability (COS). The purpose of a Solifenacin Succinate CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Solifenacin Succinate EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Solifenacin Succinate to their clients by showing that a Solifenacin Succinate CEP has been issued for it. The manufacturer submits a Solifenacin Succinate CEP (COS) as part of the market authorization procedure, and it takes on the role of a Solifenacin Succinate CEP holder for the record. Additionally, the data presented in the Solifenacin Succinate CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Solifenacin Succinate DMF.
A Solifenacin Succinate CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Solifenacin Succinate CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Solifenacin Succinate suppliers with CEP (COS) on PharmaCompass.
A Solifenacin Succinate written confirmation (Solifenacin Succinate WC) is an official document issued by a regulatory agency to a Solifenacin Succinate manufacturer, verifying that the manufacturing facility of a Solifenacin Succinate active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Solifenacin Succinate APIs or Solifenacin Succinate finished pharmaceutical products to another nation, regulatory agencies frequently require a Solifenacin Succinate WC (written confirmation) as part of the regulatory process.
click here to find a list of Solifenacin Succinate suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Solifenacin Succinate as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Solifenacin Succinate API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Solifenacin Succinate as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Solifenacin Succinate and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Solifenacin Succinate NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Solifenacin Succinate suppliers with NDC on PharmaCompass.
Solifenacin Succinate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Solifenacin Succinate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Solifenacin Succinate GMP manufacturer or Solifenacin Succinate GMP API supplier for your needs.
A Solifenacin Succinate CoA (Certificate of Analysis) is a formal document that attests to Solifenacin Succinate's compliance with Solifenacin Succinate specifications and serves as a tool for batch-level quality control.
Solifenacin Succinate CoA mostly includes findings from lab analyses of a specific batch. For each Solifenacin Succinate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Solifenacin Succinate may be tested according to a variety of international standards, such as European Pharmacopoeia (Solifenacin Succinate EP), Solifenacin Succinate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Solifenacin Succinate USP).
